KLRA Kailera Therapeutics, Inc. Insider Trading

RTW Investments (10% owner) purchased 500,000 shares of KLRA at $16.00 on 2026-04-20 ($8.0M); 4 other insiders also bought within 14 days

RTW Investments, a 10% shareholder, bought 500,000 shares at $16.00 for $8.0M on 2026-04-20, increasing holdings from 10.28M to 10.78M shares (+4.9%). This purchase is part of a cluster pattern: 4 other insiders also bought within the past 14 days. The transaction occurred on a recently listed stock (4 trading days old at current valuation), where the current price of $24.30 is notably higher than the transaction price, though direct price-performance attribution to insider motivation is not determinable from the facts presented. The concurrent buying activity by multiple insiders during the critical early trading period suggests organized accumulation rather than isolated investor activity.

Bain Capital Investors LLC buys 8,398,438 shares of KLRA at $16.00 for $134.4M, raising stake to 26.26M shares; cluster buy by 4 other insiders in 14 days

Bain Capital Investors LLC, a 10% owner, purchased 8,398,438 shares at $16.00 on 2026-04-20, expanding its stake by 47.0% to 26,255,581 shares post-transaction, just two trading days after KLRA's recent listing. Notably, 4 other insiders also bought within the past 14 days, establishing a cluster buy pattern. While the current market price of $24.61 reflects a 53.8% premium over the transaction price of $16.00, the stock is newly listed and traditional valuation anchors (52-week metrics) are not yet meaningful. This concentration of insider purchases across multiple parties shortly after IPO warrants investor scrutiny of the underlying transaction rationale and whether coordinated buying reflects confidence in near-term fundamentals or capital deployment tied to the listing mechanics.

Director Koppel Adam buys 1,562,500 shares of KLRA at $16.00 for $25,000,000; 4 other insiders also bought within 14 days

Koppel Adam, a director at Kailera Therapeutics, acquired 1,562,500 shares at $16.00 on 2026-04-20, just 2 trading days after the company's IPO listing. His post-transaction holdings of 22,583,268 shares represent a 7.4% increase from his pre-transaction position of 21,020,768 shares. The filing note indicates this transaction involves a derivative conversion rather than a straightforward open-market purchase, so the reported Table I position does not represent his complete stake. Most significantly, a cluster pattern emerges: 4 other insiders also purchased shares within the past 14 days, suggesting coordinated insider accumulation during the critical early trading window post-IPO. Given the company's 2-trading-day age and the absence of meaningful 52-week reference data, this near-simultaneous multi-insider buying activity warrants close monitoring of the underlying investment thesis and any material developments disclosed at or near the IPO.

Bain Capital Life Sciences purchased 1,562,500 shares at $16.00, raising stake to 22,583,268 shares; cluster buy pattern with 4 other insiders in past 14 days

Bain Capital Life Sciences Investors, LLC, a 10% owner, acquired 1,562,500 shares at $16.00 on 2026-04-20, increasing its position to 22,583,268 shares. The purchase occurred at a price 35% below the current market price of $24.61, which is notable given that KLRA has been publicly traded for only 2 trading days. The filing reflects a derivative-conversion transaction, meaning the investor's complete position includes derivative securities not yet fully populated in available data; this purchase represents a specific batch transaction rather than a portfolio-level move. Most significantly, this buy is part of a cluster pattern in which 4 other insiders also purchased shares within the past 14 days, suggesting broad insider confidence in valuation at the early stage of public trading. For a newly listed stock, synchronized insider accumulation across multiple stakeholders warrants close attention to the underlying fundamentals and business trajectory.

Director Kaplan Andrew T. bought 8,398,438 shares of KLRA at $16.00 for $134.4M; post-buy holdings: 26.26M shares (cluster buy pattern with 4 other insiders in 14 days).

Director Kaplan Andrew T. purchased 8,398,438 shares at $16.00 on 2026-04-20, just 2 trading days after KLRA's recent listing, increasing his holdings by 47.0% from 17.86M to 26.26M shares. This transaction is part of a cluster buy pattern—4 other insiders also bought within the past 14 days—suggesting coordinated confidence in the newly public company's valuation. The current price of $24.61 is 53.8% above the transaction price, though this reflects only 2 days of post-IPO trading and should not be interpreted as a timing signal. Note that this filing involves a derivative-conversion transaction; the insider's complete position may extend beyond Table I holdings and requires review of Table II derivative securities for full context.